The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | How can we incorporate checkpoint inhibition in microsatellite stable colorectal cancer?
Olatunji Alese, MD, Emory Winship Cancer Institute, Atlanta, GA, discusses novel strategies to further utilize immune checkpoint inhibitors in patients with microsatellite stable colorectal cancer (MSS CRC). Dual checkpoint inhibition with PD-L1 and CTLA-4 with tyrosine kinase inhibitors (TKIs) are potential regimens under investigation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
